 |
|
The unknown risks of arthritis
June 26, 2006Updates from experts at EULAR on safety and benefits data
Arthritis, in particular rheumatoid arthritis (RA), has devastating effects on the body, causing many debilitating effects and leaving many patients immobile or able to function normally. However, there are also some additional effects associated with the disease which are less well known, but just as threatening. A number of studies presented at the Annual European Congress of Rheumatology provide new data on the risks of cardiovascular diseases for RA patients, as well as some of the risks associated with the new therapies in the area, that are just beginning to emerge.
INCREASED HEART ATTACK RISKS IN RA PATIENTS DESPITE CHANGES IN DISEASE MANAGEMENT
Today (Friday 23 June), Dr. Ulf Bergström will present the results of a study showing that, despite changes in the management of rheumatoid arthritis in the last 20 years, there is no significant impact on co-morbidity related to cardiovascular diseases, in particular, related to myocardial infarction (heart attack).
As recognized by the investigators, patients with rheumatoid arthritis (RA) have a shortened lifespan when compared to people with same gender and similar age and recent studies suggest that this is largely due to increased mortality from premature cardiovascular disease, in particular myocardial infarction. As the medical field has gained a better understanding of rheumatoid arthritis, the management of it has changed significantly in terms of medical treatments and physiotherapy.
The study evaluates the effects of the changes in management of RA on the cardiovascular morbidity and mortality in patients with established RA during 1978 to 2002, by analyzing two separate patient studies from 1978 and 1995 (with an 8 year follow-up), and compared to the corresponding background population. The study found no significant changes in the cardiovascular morbidity between the two studies (standardized mortality ratios: 158 (CI: 111-225) and 168 (CI: 118-232) for the 1978 and 1995 cohorts respectively).
"The management of the disease has changed significantly over the decades and this study gives excellent measurement into whether this has had an improvement on cardiovascular events experienced by RA patients", said Dr. Bergström. "It shows that further action is necessary in order to reduce additional mortality in RA".
This study also highlights the need for further data on whether newer treatment options, such as TNF inhibitors that were introduced in Europe at the beginning of the millennium and therefore did not have a significant role in this study, will have an effect on cardiovascular events for RA patients in the future.
TNF INHIBITORS REDUCES THE RISK OF SERIOUS CARDIOVASCULAR EVENTS IN RHEUMATOID ARTHRITIS PATIENTS
Dr. William Dixon presented the results of a new study today (Friday 23 June) at the Annual European Congress of Rheumatology in Amsterdam, which shows encouraging data that treatment with TNF inhibitor reduces the risk of Myocardial Infarction (MI) and Cerebrovascular Accidents (CVA) in rheumatoid arthritis (RA) patients, when compared to patients treated with traditional DMARDs.
Recent studies suggest that the excess of deaths in rheumatoid arthritis patients is largely due to increased mortality from premature cardiovascular disease. Dr. Dixon comments, "It is already known that TNF inhibitors reduce the risk of cardiovascular events in RA patients, including less serious events. But this study has suggested that they specifically reduce the risk of myocardial infarction and cerebrovascular accidents, which are two of the most serious cardiovascular events, often leading to death". He added, "This study shows encouraging results for people with RA which could potentially reduce the mortality amongst these patients."
TNF inhibitors are a new class of drugs available for the treatment of severe rheumatoid arthritis. The drugs work by blocking the action of TNF (tumour necrosis factor), a molecule responsible for increasing levels of inflammation in people with rheumatoid arthritis. "The reason why the TNF inhibitors have shown to reduce the risk of MI and CVA could be that the events are caused by inflammatory factors, which is reduced by the TNF inhibitors' anti-inflammatory effects", said Dr. Dixon.
INCREASED RISK OF SERIOUS INFECTIONS WITH TNF INHIBITOR TREATMENT
Treatment with TNF inhibitors might increase the risk of common serious infections, according to a new study, presented at the Annual European Congress of Rheumatology in Amsterdam by Dr. Johan Askling on Friday (23 June).
As recognized by the investigators of the study, it is already established that TNF inhibitors increases the risk for intracellular infections such as TB. The risk for much more common, yet still serious, infections remains less clear. Studies from clinical practice have shown mixed results, and taken together, clinical trials indicate the possibility for a risk increase of clinical significance.
The infections that were included in the study were respiratory, septicaemia, articular, gastrointestinal, cutaneous, or other infections leading to hospitalisation.
Based on 422 hospitalizations with infection, the study concluded that, if treated with TNF inhibitors, the patients experienced a 20 to 30%-increase in risk of hospitalizations related to infections.
"The reason for this drug-related increase in risk of infections is not yet clear, although our results demonstrate a lower degree of risk increase than what was recently suggested based on trial data. However, since part of the drugs' very action is to interfere with the body's normal defense against infections, some degree of risk increase is fully conceivable", Dr. Askling said. "TNF inhibitors drugs have showed great effectiveness for many patients and is an excellent example that raises the discussion of whether, or when, the benefits the drugs outweighs any risks associated with them", Dr. Askling added.
European League Against Rheumatism
As recognized by the investigators, patients with rheumatoid arthritis (RA) have a shortened lifespan when compared to people with same gender and similar age and recent studies suggest that this is largely due to increased mortality from premature cardiovascular disease, in particular myocardial infarction. As the medical field has gained a better understanding of rheumatoid arthritis, the management of it has changed significantly in terms of medical treatments and physiotherapy.
The study evaluates the effects of the changes in management of RA on the cardiovascular morbidity and mortality in patients with established RA during 1978 to 2002, by analyzing two separate patient studies from 1978 and 1995 (with an 8 year follow-up), and compared to the corresponding background population. The study found no significant changes in the cardiovascular morbidity between the two studies (standardized mortality ratios: 158 (CI: 111-225) and 168 (CI: 118-232) for the 1978 and 1995 cohorts respectively).
"The management of the disease has changed significantly over the decades and this study gives excellent measurement into whether this has had an improvement on cardiovascular events experienced by RA patients", said Dr. Bergström. "It shows that further action is necessary in order to reduce additional mortality in RA".
This study also highlights the need for further data on whether newer treatment options, such as TNF inhibitors that were introduced in Europe at the beginning of the millennium and therefore did not have a significant role in this study, will have an effect on cardiovascular events for RA patients in the future.
TNF INHIBITORS REDUCES THE RISK OF SERIOUS CARDIOVASCULAR EVENTS IN RHEUMATOID ARTHRITIS PATIENTS
Dr. William Dixon presented the results of a new study today (Friday 23 June) at the Annual European Congress of Rheumatology in Amsterdam, which shows encouraging data that treatment with TNF inhibitor reduces the risk of Myocardial Infarction (MI) and Cerebrovascular Accidents (CVA) in rheumatoid arthritis (RA) patients, when compared to patients treated with traditional DMARDs.
Recent studies suggest that the excess of deaths in rheumatoid arthritis patients is largely due to increased mortality from premature cardiovascular disease. Dr. Dixon comments, "It is already known that TNF inhibitors reduce the risk of cardiovascular events in RA patients, including less serious events. But this study has suggested that they specifically reduce the risk of myocardial infarction and cerebrovascular accidents, which are two of the most serious cardiovascular events, often leading to death". He added, "This study shows encouraging results for people with RA which could potentially reduce the mortality amongst these patients."
TNF inhibitors are a new class of drugs available for the treatment of severe rheumatoid arthritis. The drugs work by blocking the action of TNF (tumour necrosis factor), a molecule responsible for increasing levels of inflammation in people with rheumatoid arthritis. "The reason why the TNF inhibitors have shown to reduce the risk of MI and CVA could be that the events are caused by inflammatory factors, which is reduced by the TNF inhibitors' anti-inflammatory effects", said Dr. Dixon.
INCREASED RISK OF SERIOUS INFECTIONS WITH TNF INHIBITOR TREATMENT
Treatment with TNF inhibitors might increase the risk of common serious infections, according to a new study, presented at the Annual European Congress of Rheumatology in Amsterdam by Dr. Johan Askling on Friday (23 June).
As recognized by the investigators of the study, it is already established that TNF inhibitors increases the risk for intracellular infections such as TB. The risk for much more common, yet still serious, infections remains less clear. Studies from clinical practice have shown mixed results, and taken together, clinical trials indicate the possibility for a risk increase of clinical significance.
The infections that were included in the study were respiratory, septicaemia, articular, gastrointestinal, cutaneous, or other infections leading to hospitalisation.
Based on 422 hospitalizations with infection, the study concluded that, if treated with TNF inhibitors, the patients experienced a 20 to 30%-increase in risk of hospitalizations related to infections.
"The reason for this drug-related increase in risk of infections is not yet clear, although our results demonstrate a lower degree of risk increase than what was recently suggested based on trial data. However, since part of the drugs' very action is to interfere with the body's normal defense against infections, some degree of risk increase is fully conceivable", Dr. Askling said. "TNF inhibitors drugs have showed great effectiveness for many patients and is an excellent example that raises the discussion of whether, or when, the benefits the drugs outweighs any risks associated with them", Dr. Askling added.
European League Against Rheumatism
Arthritis Current Events and Arthritis News RSSMultiple health concerns surface as winter, vitamin D deficiences arrive
A string of recent discoveries about the multiple health benefits of vitamin D has renewed interest in this multi-purpose nutrient, increased awareness of the huge numbers of people who are deficient in it, spurred research and even led to an appreciation of it as "nature's antibiotic."
Can EP4 agonist alleviate gastric lesions?
Over 300 million patients use non-steroidal anti-inflammatory drugs (NSAIDs) in the world to treat pain, arthritis, fever and other diseases. Nearly 30% of the users suffer from gastric lesions and bleeding.
Thoughtful words help couples stay fighting fit
Couples who bring thoughtful words to a fight release lower amounts of stress-related proteins, suggesting that rational communication between partners can ease the impact of marital conflict on the immune system.
Penn Study Provides First Clear Idea of How Rare Bone Disease Progresses
An international team of scientists, led by researchers at the University of Pennsylvania School of Medicine, is taking the first step in developing a treatment for a rare genetic disorder called fibrodysplasia ossificans progressiva (FOP), in which the body's skeletal muscles and soft connective tissue turns to bone, immobilizing patients over a lifetime with a second skeleton.
Aileron collaborates study in Nature: Stapled peptides inhibit Notch1 transcription factor
This research validates the potential for Stapled Peptides to modulate key intracellular biological targets, such as transcription factors, that have not been addressable with current small molecule or biologic drug modalities.
Researchers find new way to attack inflammation in Graves' eye disease
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab.
Common Pain Relievers May Dilute Power of Flu Shots
With flu vaccination season in full swing, research from the University of Rochester Medical Center cautions that use of many common pain killers - Advil, Tylenol, aspirin - at the time of injection may blunt the effect of the shot and have a negative effect on the immune system.
Mending meniscals in children, improving diagnosis and recovery
The meniscus is a rubber-like, crescent moon-shaped cartilage cushion that sits between the leg and thigh bone. Each knee has two menisci: one on the inside of the knee joint and one on the outside.
Study finds link between childhood physical abuse and arthritis
Adults who had experienced physical abuse as children have 56 per cent higher odds of osteoarthritis compared to those who have not been abused, according to a new study by University of Toronto researchers.
Pain thresholds linked to inflammation and sleep problems in arthritis patients
Despite recent advances in anti-inflammatory therapy, many rheumatoid arthritis (RA) patients continue to suffer from pain.
More Arthritis Current Events and Arthritis News Articles
 |
Imak Arthritis Gloves Medium (Pack of 2) by IMAK The IMAK Arthritis Gloves help relieve aches, pains and stiffness associated with Arthritis of the hands. The unique design provides mild compression, offers warmth and helps increase circulation and promote healing. The Arthritis Gloves are made of soft |
 |
Conquering Arthritis: What Doctors Don't Tell You Because They Don't Know by Barbara D Allan (Author) This book is newly revised and updated with important updates that make healing from arthritis even easier and quicker. It has been used with great success by many people with rheumatoid arthritis, osteoarthritis, and other forms of arthritis, to heal themselves. It provides practical, detailed information that is critical for the successful healing of arthritis, but that has never before been collected in one place. The information is organized into a well-researched, easy-to-follow plan for getting well again and includes case histories of people with dramatic and lasting recoveries. It focuses not just on coping with the symptoms of arthritis, but on correcting its underlying causes using proven alternative medicine and pain management techniques. ... |
 |
Arthritis Advantage-Once Daily Arthritis Therapy, 96 Caplets (3 Pack) by Digestive Advantage |
 |
Arthritis Advantage for Arthritis Dietary Supplement Caplets, 32-Count Box (Pack of 2) by Arthritis Advantage APR Arthritis Advantage for relief of arthritis symptoms |
 |
The Arthritis Cure, Revised and Updated: The Medical Miracle That Can Halt, Reverse, And May Even Cure Osteoarthritis by Jason Theodosakis (Author), Sheila Buff (Author), Barry Fox (Author) Since its original publication in 1996, The Arthritis Cure has swept the nation, providing amazing relief for the millions who suffer chronic arthritis pain. By outlining a nine-point program that includes a new effective supplement, ASU, The Arthritis Cure Revised Edition describes a program that can halt, reverse, and possibly even cure degenerative osteoarthritis. Based on the most recent and cutting-edge medical research, this invaluable resource promises readers: --The latest research indicating that prescription arthritis drugs are not only expensive but can also be dangerous--they can raise blood pressure and damage the kidneys. --New studies supporting the use of glucosamine and chondroitin to treat arthritic symptoms. --Dr. Theodosaki's ratings of the current... |
 |
Arthritis Dexterity Kit - Set of 11 Aids for Daily Living by Distributed by Wellhaven Gifts for Seniors & Boomers Make everyday tasks easier with the Dexterity Kit. It contains 11 products that help provide arthritis pain relief. The Dexterity Kit contains: 1 Folding Zipper & Button Puller - for home or travel use, 2 Spoon & Fork Holders - removable - use with your existing silverware, 2 Lamp Switch Enlargers - no permanent installation required, 3 Pen and Pencil Cushions - use on artist paint brushes, knitting needles, etc., 3 E-Z Key Turners - 3 different colors for key color coding |
 |
Arthritis Gloves - Medium - 1 pair by Imak IMAKs® Arthritis Gloves are designed to help relieve aches, pains, and stiffness associated with arthritis of the hands. The unique design of the IMAK Arthritis Gloves provides mild compression for warmth and helps increase circulation, which ultimately reduces pain and promotes healing. The Arthritis Gloves are made of soft, breathable cotton Lycra®, meaning they are comfortable enough to wear all day and night. The open fingertips allow you complete freedom to feel, touch and grip, so you can perform daily tasks without issue. |
 |
Arthritis, What Exercises Work: Breakthrough Relief For The Rest Of Your Life, Even After Drugs & Surgery Have Failed by Dava Sobel (Author), Arthur C. Klein (Author) What is the most powerful arthritis treatment ever developed to help restore you to a healthy, pain-free, and vigorous life--for the rest of your life? It's the very same breakthrough that has: --Helped more arthritis sufferers than drugs, surgery, or any other treatment--without dangerous side effects. --Been widely prescribed by medical doctors and other health practitioners. The answer? Exercise. Here are the right exercises for your kind of arthritis, pain-level, age, occupation, and hobbies. And they're the most effective exercises for arthritis available anywhere--rated "best" by arthritis sufferers themselves in an unprecedented nationwide survey...supported by medical doctors...and backed by the latest research. only this book has them. Let... |
 |
Duro-Med Arthritis Natural Pain Relief Microwavable Therabead Moist Heat Standard Pack with Cover, 9 X 12 by Duro-Med Duro-Med Industries' amazing Therabeads microwaveable heat products represent a major breakthrough in moist heat therapy. TheraBeads delivers moist heat safely and effectively. By utilizing the convenience of a microwave oven, TheraBeads provide therapeutic moist heat at the correct temperature levels needed for effective therapy. Full 9"x12" size is ideal for most parts of the body including shoulders, knees and back. Deliver uniform moist heat to help relieve soreness and stiffness. With proper care Therabeads can be used indefinately. Includes wrap cover. |
 |
How to Eat Away Arthritis: Gain Relief from the Pain and Discomfort of Arthritis Through Nature's Remedies by Laurie M. Aesoph (Author) This revised and expanded edition of the perennially popular self-help book details how arthritis sufferers can improve their conditions with the foods they eat. Using the simple dietary procedures described in this book, readers can reverse some cases of osteoarthritis or rheumatoid arthritis without expensive drugs or equipment. |
| © 2009 BrightSurf.com |